Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
Zacks Investment Research | Jun 11, 2019 10:30PM ET
Denali Therapeutics Inc. (NASDAQ:DNLI) announced that the FDA has granted an orphan drug status and a rare pediatric disease designation to its pipeline candidate, DNL310. The pre-clinical candidate is being evaluated for the treatment of patients with mucopolysaccharidosis II (MPS II), also known as Hunter Syndrome, which is a lysosomal storage disease caused by the IDS enzyme deficiency.
Denali plans to begin a phase I/II study on DNL310 for treating Hunter Syndrome in 2020.
In earlier pre-clinical studies, DNL310 demonstrated an increased brain uptake in a relevant disease model and robust reduction of downstream markers of disease in the central nervous system compared with the standard enzyme replacement therapy (ERT).
Notably, the orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200,000 people in the United States. This designation also makes the company entitled to certain other benefits including tax credits related to clinical trial expenses and an exemption from the FDA user fee. On winning a nod from the regulatory agency, the status will also make DNL310 eligible for seven years of marketing exclusivity in the United States.
Additionally, the rare pediatric disease designation granted to DNL310 provides Denali with an opportunity to obtain a pediatric disease Priority Review Voucher from the FDA after the candidate’s qualifying new drug application (NDA) is approved for the treatment of any rare pediatric disease. The company may use the voucher to procure a priority review for an NDA submitted later.
Shares of Denali were up almost 1.5% following the announcement of this news on Tuesday. However, the stock has lost 8.4% so far this year against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.